Canonsburg, Pennsylvania-based Viatris Inc. (VTRS) is a global healthcare company that develops, manufactures, and markets branded medicines, generic drugs, complex generics, biosimilars, and over-the-counter products. Valued at a market cap of $19.8 billion, Viatris aims to expand access to affordable, high-quality medicines worldwide.
The healthcare titan is expected to release its Q2 2026 earnings before the market opens on Thursday, Aug. 6. Ahead of the event, analysts expect the company’s EPS to be $0.62 on a diluted basis, flat from the year-ago quarter. The company has exceeded Wall Street’s EPS estimates in each of its last four quarters.
